TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02870738

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pelvic Floor Physical Therapy
Description: Internal and/or external myofascial release of the pelvic floor muscles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bladder Instillations
Description: A solution of heparin sulphate 40,000 IU (4 cc of 10,000 units/cc), lidocaine 2% 16 ml, Sodium bicarbonate 8.4% 4 ml and Kenalog 40 mg (1cc) to reach a total fluid volume of 25 ml will be instilled into the bladder with a urinary catheter
Study: NCT04904692

Intervention type: PROCEDURE
Intervention: Blood draw
Description: 8x9mL EDTA tubes. In subjects treated with hydroxychloroquine treatment an extra EDTA tube (4mL) will be collected for the REVIVE substudy.

Intervention type: PROCEDURE
Intervention: Blood draw
Description: 8x9mL EDTA tubes. In subjects treated with hydroxychloroquine treatment an extra EDTA tube (4mL) will be collected for the REVIVE substudy.

Intervention type: PROCEDURE
Intervention: Bronchoalveolar lavage
Description: Only in case of diagnostic or therapeutic indication.

Intervention type: PROCEDURE
Intervention: Bronchoalveolar lavage
Description: Only in case of diagnostic or therapeutic indication.

Intervention type: PROCEDURE
Intervention: SARS CoV-2 swabs
Description: Nasopharyngeal, oropharyngeal and nasal swabs
Study: NCT02257567

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab standard dose, 375 mg/m\^2 IV on Day 1 of each cycle for up to 6 cycles (each cycle is 21 days in DLBCL and 28 days in FL).
Study: NCT04904692

Intervention type: PROCEDURE
Intervention: SARS CoV-2 swabs
Description: Nasopharyngeal, oropharyngeal and nasal swabs
Study: NCT04445753

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tai Chi exercise
Description: Individuals in the intervention group will perform a 12-week Tai Chi exercise in company with a researcher.Following the warm-up movements (Qi-gong), the training protocol of the Tai Chi movements, which includes the 10-form Yang style, will continue for 12 weeks, with two sessions per week determined by the researchers.The first and second weeks of the exercise protocol will include introducing the Tai Chi philosophy and teaching 10 forms of Yang style to patients. For 12 weeks, individuals will practice 10 forms of Tai Chi exercises with a researcher in each session. Each session will be planned as one hour.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Education (control group)
Description: Individuals in the control group will also be trained on heart failure, which will be applied to individuals in the intervention group. The only attempt to be made to the control group will be education.
Study: NCT01325077

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: model of health care service
Description: Conventional model(C): Nurses give fixed-dose analgesic according to surgeons' prescription Study model(S): Nurses give initial-dose analgesic according to surgeons' prescription. In case of inadequate pain relief, another half of initial dose will be given twice at 15-min interval and acute pain service will be consulted if there is still pain.
Study: NCT00006359

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LHRH agonist
Description: Lupron: 22.5mg IM injection q 12 wks x 2 OR Zoladex: 10.8 mg subQ injection q 12 wks x 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: antiandrogen
Description: flutamide 250 mg PO tid for 4 wks OR casodex 50 mg PO daily for 4 wks

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: 4500 cGy total dose given days 1-5 for 5 weeks following initiation of androgen suppression (25 fractions)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Brachytherapy boost
Description: Iodine 125 0.3 to 0.5 U per seed OR palladium 103 1.04 to 1.4 U per seed as implant; prescribed dose of I-125 100 Gy (TG-43) and Pd-103 90 Gy
Study: NCT00434317

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Study: NCT04092504

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: gero-erat
Description: The intervention is a standardize Care Plan which will be developed based on the evidence of caring for elderly patients in a trauma setting. The Care Plan will have its base in, the concept of ERAS and CGA. Also, patient experience will be taken in consideration and complement the care pathway.~Patients admitted to the trauma unit will be given the care and asked to be a part of the study witch include to fill out surveys at baseline, six months and 1 year.
Study: NCT01894139

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-Protein/Low-GI Diet

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low-protein/High-GI Diet
Study: NCT00687596

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAC-101
Description: Participants were randomized to TAC 101 received TAC 101 20 mg (administered as 2 10 mg formulated tablets) PO daily with approximately 240 mL (8 oz) of water under fed conditions (no later than 1 hour after a meal) for 14 days followed by a 7 day recovery period. This cycle was repeated every 21 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants randomized to placebo received 2 placebo tablets (identical in appearance to the TAC 101 tablets) administered PO daily with approximately 240 mL (8 oz) of water under fed conditions (no later than 1 hour after a meal) in a regimen identical to that for TAC 101.
Study: NCT04361396

Intervention type: OTHER
Group type: OTHER
Intervention: Collection of samples
Description: Only in enrolled patient : different samples will be taken at different times of the surgery (3 samples of pneumoperitoneum, 1 sample of peritoneal effusion or peritoneal lavage fluid and 1 sample of bile, in case of cholecystectomy.
Study: NCT04584255

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Predetermined dosage PO Daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Predetermined dosage PO Daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Predetermined dosage PO Daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dostarlimab
Description: Predetermined Dosage, IV,q3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dostarlimab
Description: Predetermined Dosage, IV,q3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dostarlimab
Description: Predetermined Dosage, IV,q3 weeks
Study: NCT04230759

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: Patients receive chemotherapy cycles as followed:~Mitomycin-C 12 mg/m², day 1 (maximum single dose 20 mg) 5-FU: 1000 mg/m² per day, continuous i.v. infusion, on day 1-4 and 29-32

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Patients receive chemotherapy cycles as followed:~Mitomycin-C 12 mg/m², day 1 (maximum single dose 20 mg) 5-FU: 1000 mg/m² per day, continuous i.v. infusion, on day 1-4 and 29-32

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation
Description: PTV_A (primary tumor): T1-T2\<4cm N+: 28 x 1.9 Gy=53.2 Gy, five fractions per week or PTV_A (primary tumor): T2\>=4cm, T3-4 Nany: 31 x 1.9 Gy=58.9 Gy, five fractions per week PTV_N (involved node): 28 x 1.8 Gy=50.4 Gy, five fractions per weeks PTV_Elec (elective node): 28 x 1.43 Gy=40.0 Gy, five fractions per week

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: PTV_A (primary tumor): T1-T2\<4cm N+: 28 x 1.9 Gy=53.2 Gy, five fractions per week or PTV_A (primary tumor): T2\>=4cm, T3-4 Nany: 31 x 1.9 Gy=58.9 Gy, five fractions per week PTV_N (involved node): 28 x 1.8 Gy=50.4 Gy, five fractions per weeks PTV_Elec (elective node): 28 x 1.43 Gy=40.0 Gy, five fractions per week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: 1500 mg, 1h-civ, every 4 weeks (q4w) applied on day -14 (that is 14 days prior to initiation of RCT), day 15 (during RCT), and thereafter q4w (+/- 3d) for a total of 12 doses
Study: NCT04244253

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPC-64005 20 mg , Once-daily
Description: Active, High Dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPC-64005 10 mg , Once-daily
Description: Active, Low Dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo, Once-daily
Description: Placebo
Study: NCT02339974

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Heterotopic Implantation Of the Edwards-Sapien XT Transcatheter Valve in the Inferior VEna Cava
Study: NCT02730858

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Palliative and Oncology Care
Description: Patients randomized to the intervention will receive collaborative care from palliative care and oncology for the remainder of their illness. The initial five visits with palliative care will be conducted in accordance with the study specific clinical practice guidelines and occur at least monthly.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Oncology Care
Description: Patients randomized to oncology care alone will continue to receive routine care identical to what they would have received if they had not participated in the trial. Either patients or their oncologists can request palliative care consultation at any point in time.
Study: NCT02257567

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab standard dose, 375 mg/m\^2 IV on Day 1 of each cycle for up to 6 cycles (each cycle is 21 days in DLBCL and 28 days in FL).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab standard dose, 375 mg/m\^2 IV on Day 1 of each cycle for up to 6 cycles (each cycle is 21 days in DLBCL and 28 days in FL).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polatuzumab vedotin (Lyophilized)
Description: Participants in the New Formulation (NF) Cohort (Arms G and H) will follow the same schedule and dosing requirements as participants in the other Phase II cohorts (Arms A-F).
Study: NCT01752426

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heavy Water (2H2O)
Description: 50 ml 70% 2H2O 3 times a day for the first 5 days followed by 60 ml daily for a total of 4 weeks. After the 5-day loading period, a 60 ml maintenance dose of 2H2O will be drunk at bedtime. At end of the 4th week, subjects stop drinking 2H2O (washout phase) and be followed from 6-12 weeks until beginning treatment with PCI-32765.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PCI-32765
Description: 420 mg orally once daily.
Study: NCT02210572

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bimuno Galacto-oligosaccharide 1.37 g/d
Description: Prebiotic versus low-FODMAPs diet

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Low- FODMAPs diet
Study: NCT04413500

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reminder
Description: A reminder to take the anti-hypertension medication with adjustable frequency.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational message
Description: An educational message to increase the knowledge about various facts around hypertension. The short messages are supposed to be sent based on the patient's needs.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational messages
Description: The motivational short messages to increase the motivational levels.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: showing trends
Description: Short messages contain different trends of medication intake rate, BP, physical activity rate, and so on.
Study: NCT04205448

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical exercize
Description: 10 weeks group exercize followed by community-based voluntary exercize
Study: NCT02278510

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan
Description: Topotecan is a chemotherapy that is approved by the FDA to treat cancers. It is normally given by an intravenous injection, and not directly into a tumor. That is why it is considered to be an investigational drug for this study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadolinium DTPA
Description: Gadolinium DTPA is a contrast agent which will be added to topotecan to allow the investigators to observe where topotecan goes in tumors. Gadolinium DTPA is approved by the FDA for intravenous injection during an MRI scan. It is not approved by the FDA for administration directly into a tumor.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cleveland Multiport Catheter
Description: The Cleveland Multiport Catheter is a device that is not approved by the FDA and so it is classified as an investigational device. It has been designed to deliver drugs and other agents intended to treat cancers directly into the affected tissues. The Cleveland Multiport Catheter can be placed into a brain tumor only in the operating room. It is placed during an operation to perform a biopsy of brain tumors. Following the biopsy, a surgeon will place two catheters into the tumor with use of an image guided navigation system. Once each catheter has been placed, it will be secured into the scalp and the incision will be closed. The Cleveland Multiport Catheter will be left in place until the completion of the topotecan treatment.
Study: NCT03439306

Intervention type: DEVICE
Intervention: Pulse Oximeter
Description: The Pulse Oximeter are placed on the left and right Index fingers of each subject of the healthy adult volunteer group to evaluate the SpO2 accuracy performance.
Study: NCT02064803

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Gastro-entero anastomosis only
Description: Gastro-entero anastomosis only

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gastric partitioning Plus Gastro-entero anastomosis
Description: Gastric partitioning Plus Gastro-entero anastomosis
Study: NCT04195646

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EndoVigilant CAD Software
Description: The CAD software is deep learning algorithm used to aid in the detection of polyps (abnormal tissue growths in the wall of the colon and adenomas (pre-cancerous growths) during colonoscopy. In its current form, the CAD software is installed on a computer system unit that utilizes an an operating system.
Study: NCT01729741

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: drain was inserted after thyroid surgery
Description: insertion of drain after thyroid surgery
Study: NCT00005942

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liposomal daunorubicin citrate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaxanib
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT02257567

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polatuzumab vedotin (Lyophilized)
Description: Participants in the New Formulation (NF) Cohort (Arms G and H) will follow the same schedule and dosing requirements as participants in the other Phase II cohorts (Arms A-F).
Study: NCT04558060

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Standardized Patient
Description: Computer program that presented a virtual human patient

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Academic Study
Description: Study of a summary of motivational interviewing concepts and techniques.
Study: NCT02587676

Intervention type: OTHER
Intervention: Evatouch Super
Description: The deterioration of RDLs may differ between in vitro conditions and the conditions encountered in denture wearers. We conducted an in vivo study to investigate how resilient denture liners (RDLs) changed in hardness when embedded in complete maxillary dentures worn by patients for one month in a clinical setting. We hypothesized that the hardness one month after application of the RDLs would be affected by the age, the condition of the saliva, the occlusal force, type of denture used, the patients habits related to smoking, drinking, wearing dentures while sleeping, and using a denture cleanser.
Study: NCT02006472

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pridopidine
Description: 22.5 mg and 45 mg capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pridopidine
Description: 22.5 mg and 45 mg capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pridopidine
Description: 22.5 mg and 45 mg capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pridopidine
Description: 22.5 mg and 45 mg capsules

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules matching drug

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Capsules matching drug

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Capsules matching drug

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Capsules matching drug

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Capsules matching drug
Study: NCT01553656

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cabozantinib capsules
Description: cabozantinib capsules administered as 25-mg and 100-mg strengths once-daily until disease progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cabozantinib tablets
Description: cabozantinib tablets administered as 20-mg and 60-mg strengths once-daily until disease progression
Study: NCT00576355

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interpersonal and Social Rhythm Therapy for Adolescents (IPSRT-A)
Description: IPSRT-A involves 20 weeks of individual therapy, incorporating informed psychological, behavioral, and practical strategies adapted to the developmental needs of adolescents.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment As Usual (TAU)
Description: TAU includes the offering of educational information about bipolar disorder and referral to a mental health provider.
Study: NCT04690686

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LW-02 device immunopheresis combined with atezolizumab
Description: The LW-02 device comprises an immunoadsorption affinity column, employing a proprietary human recombinant protein, single chain TNF-α ligand, covalently linked to a bead resin, that both enhances the capture efficiency of sTNF-Rs while avoiding complications from column leaching. Reduced sTNF-R plasma levels may lead to objective tumor responses. In combined treatment arm the immunopheresis procedure is combined with standard dose immunotherapy (atezolizumab) to potentially enhancing its cytotoxic effect.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LW-02 device immunopheresis combined with weekly paclitaxel
Description: The LW-02 device comprises an immunoadsorption affinity column, employing a proprietary human recombinant protein, single chain TNF-α ligand, covalently linked to a bead resin, that both enhances the capture efficiency of sTNF-Rs while avoiding complications from column leaching. Reduced sTNF-R plasma levels may lead to objective tumor responses. In combined treatment arm the immunopheresis procedure is combined with low dose chemotherapy to potentially enhancing its cytotoxic effect.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LW-02 device immunopheresis
Description: The LW-02 device comprises an immunoadsorption affinity column, employing a proprietary human recombinant protein, single chain TNF-α ligand, covalently linked to a bead resin, that both enhances the capture efficiency of sTNF-Rs while avoiding complications from column leaching. Reduced sTNF-R plasma levels may lead to objective tumor responses.
Study: NCT03558659

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Positional therapy belt
Description: The positional therapy belt produced by SlumberBUMP will be used by stroke patients during sleep, which helps to avoid sleep in the supine position.
Study: NCT01239953

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Coronary angioplasty using the paclitaxel-eluting balloon
Description: Balloon angioplasty

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Coronary angioplasty using the everolimus-eluting stent
Description: Stent implantation
Study: NCT03848325

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep deprivation
Description: Eight hour opportunity for sleep followed by 24 hours of sleep deprivation.
Study: NCT01460212

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SSRI antidepressants
Description: SSRI antidepressants are Selective serotonin reuptake inhibitors. They include fluoxetine (Prozac); sertraline (Zoloft); paroxetine (Paxil); citalopram (Celexa) ;escitalopram (Lexapro) and fluvoxamine (Luvox). It will be chosen according to special condition of every patient.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavior Therapy
Description: The essence of CBT is a learning process through which an appropriate pattern in cognitive and behavioral could be learn and stored as memory
Study: NCT03774732

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Irradiation technique (3D-CRT or SABR) will be at physician discretion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: pembrolizumab will be administered as per standard of care every 3 weeks until progression or toxicity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: pembrolizumab will be administered as per standard of care every 3 weeks until progression or toxicity

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: for squamous NSCLC carboplatin AUC6, paclitaxel 200 mg/m² every 3 weeks for 4 cycles; for non-squamous NSCLC carboplatin AUC5 or cisplatin 75 mg/m² every 3 weeks for 4 cycles, and pemetrexed 500 mg/m² every 3 weeks until progression or toxicity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: for squamous NSCLC carboplatin AUC6, paclitaxel 200 mg/m² every 3 weeks for 4 cycles; for non-squamous NSCLC carboplatin AUC5 or cisplatin 75 mg/m² every 3 weeks for 4 cycles, and pemetrexed 500 mg/m² every 3 weeks until progression or toxicity
Study: NCT03909152

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Onapristone ER
Description: 50 mg PO BID (with dosage adjustments) until POD, unacceptable toxicity or withdrawal of consent.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Onapristone ER
Description: 50 mg PO BID (with dosage adjustments) until POD, unacceptable toxicity or withdrawal of consent.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Onapristone ER
Description: 50 mg PO BID (with dosage adjustments) until POD, unacceptable toxicity or withdrawal of consent.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Onapristone ER + Anastrozole
Description: Onapristone ER Patients will take 50 PO BID in the form of two 20 mg tablets and one 10 mg tablet taken with food and water twice daily. Patients will be prescribed anastrozole 1mg PO QD. Anastrozole will be taken once daily in the AM with patients morning dose of onapristone ER.